Similar articles

• Nitric oxide in sepsis-syndrome: potential treatment of septic shock by nitric oxide synthase antagonists.

  Ketteler M, Cetto C, Kirdorf M, Jeschke GS, Schäfer JH, Distler A. Ketteler M, et al. Kidney Int Suppl. 1998 Feb;64:S27-30. Kidney Int Suppl. 1998. PMID: 9475485 Review.
• Systemic toxins. Signs, symptoms & management of patients in septic shock.

  Lent M, Hirshberg A, Margolis G. Lent M, et al. JEMS. 2001 Dec;26(12):54-65; quiz 66-7. JEMS. 2001. PMID: 11771375 No abstract available.
• [Management of neonatal sepsis and septic shock].

  Wojsyk-Banaszak I, Szczapa J. Wojsyk-Banaszak I, et al. Przegl Epidemiol. 2006;60(1):119-26. Przegl Epidemiol. 2006. PMID: 16758750 Review. Polish.
• Acute left ventricular dilation and septic shock-induced myocardial dysfunction.

  Robin E, Tavernier B. Robin E, et al. Crit Care Med. 2009 Oct;37(10):2862; author reply 2862-3. doi: 10.1097/CCM.0b013e3181b3a131. Crit Care Med. 2009. PMID: 19865025 No abstract available.
• [Nitric oxide--a basic mediator of vasodilation and septic shock].

  Vasilev D, Karadimov D, Vogt J, Santak B. Vasilev D, et al. Khirurgiia (Sofiia). 1996;49(4):14-6. Khirurgiia (Sofiia). 1996. PMID: 8968135 Review. Bulgarian.